Omnigel, the leading pain relief brand under Cipla Health Limited, has strengthened its portfolio with the introduction of Omnigel Maxstrong. This new variant is specifically designed for individuals with active lifestyles who frequently experience muscle and joint discomfort. The launch marks Omnigel's entry into the 2% diclofenac category, an advanced formulation increasingly adopted across the industry for effective pain management.
Product Features and Formulation
Omnigel Maxstrong is formulated to provide 5X Action and long-lasting relief, targeting recurring pain that often accompanies daily physical activities. The product aims to help users maintain consistency in their routines by reducing discomfort. The brand emphasizes that the new variant is built for those who deal with muscle and joint pain more often than usual, particularly as part of an active everyday life.
First Sub-Brand and New Packaging
The launch represents a significant milestone for Omnigel, as it introduces its first sub-brand along with a distinctive packaging design. The new look conveys a contemporary and premium identity while retaining recognizable elements such as the brand's signature red palette and core pain relief cues. This approach ensures continuity with Omnigel's existing brand equity while signaling innovation.
Availability in Multiple Formats
Omnigel Maxstrong will be available in gel (30 gm) and spray formats (35 gm, 55 gm, 75 gm, and 100 gm). This expansion across multiple formats caters to varying consumer preferences, offering flexibility in application and dosage. The spray option, in particular, provides convenience for on-the-go use.
Brand's Commitment to Pain Management
Omnigel continues to build on its core promise of enabling effective pain management, with solutions aimed at supporting sustained movement in everyday life. The brand's portfolio now includes a range of products addressing different pain relief needs, from acute muscle soreness to chronic joint discomfort.
About Cipla Health Limited
Cipla Health Limited, the fast-moving wellness goods (FMWG) arm of Cipla, was incorporated in 2015 with a vision to spearhead the wellness wave in India. The company has delivered rapid growth and today plays across a diverse portfolio of 20 brands, with most key brands being No. 1 or No. 2 in their respective categories. The portfolio includes products in Pain Care (Omnigel), Smoking Cessation (Nicotex), Oral Rehydration Solutions (Prolyte), Medicated Ointments (Cipladine), Cough & Cold (Cofsils and Naselin), Multi Vitamins (Maxirich), Weight Gain (Endura Mass), and Personal Care (Rivela Dermascience, Cetafresh, Tugain Essentials, Astaberry).
